GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...
GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...
Hosted on MSN9mon
GSK blood cancer therapy nearly triples survival in late stage trialAs for DREAMM-7’s primary endpoint of progression-free survival, the Blenrep combination indicated a statistically significant and clinically meaningful improvement. There was a 59% reduction in ...
The pharma group reported top-line results from the DREAMM-7 study this morning, showing a greater benefit for Blenrep (belantamab mafodotin) compared to Genmab and Johnson & Johnson’s anti-CD37 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback